Ignite Creation Date:
2024-05-06 @ 1:35 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01847716
Status:
TERMINATED
Last Update Posted:
2018-09-26
First Post:
2013-04-19
Brief Title:
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Status:
TERMINATED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
numbers recruited to show adequate association but not primary outcome
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary arterial hypertension PAH is a disease that causes raised blood pressure in blood vessels that pick up oxygen from the lungs It has a life expectancy similar to some cancers There is treatment available but there is no cure We now know that PAH is associated with weakness in the muscles in the legs which contributes to the symptoms patients experience Researchers believe that certain proteins found in high levels in the blood of patients with other chronic diseases can affect muscle function and growth One of these proteins is called growth differentiating factor GDF 8 high levels of which are associated with muscle weakness in chronic obstructive pulmonary diseaseCOPD and heart failure HF Interestingly there are drugs available which block the actions of GDF-8 on muscle cells which has been shown in animals to result in increased muscle size A related protein called GDF-15 is found in elevated levels in patients PAH and is linked to prognosis Our preliminary data suggests that GDF-15 can also directly influence muscle size in a number of situations We aim to investigate the role of GDF-15 and related molecules in the development of muscle weakness in patients with PAH We will do this by measuring certain markers of muscle weakness and taking blood and muscle samples in patients and controls We will then compare the levels of GDF-15 in these tissues in those with and without muscle wasting We hope this work will lead to a greater understanding of the role of GDF-15 in the development of muscle weakness in patients with PAH GDF-15 levels may be important in allowing us to define which patients have muscle weakness In the future we aim to perform a clinical trial of drugs which block the actions of GDF-15
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None